StockData
RGCNasdaqMedicinal Chemicals & Botanical Products

Regencell Bioscience Holdings Ltd

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026
$10.05+0.46 (+4.80%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Regencell Bioscience Holdings Ltd revenue by segment

No segment breakdown reported

Regencell Bioscience does not break out revenue by segment, region or product in the tagged data of its filings for this period type.